BHV-7000 for Bipolar Disorder

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Biohaven Therapeutics Ltd.

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.

Eligibility Criteria

This trial is for adults aged 18-75 with a BMI of ≥18 and ≤35, diagnosed with bipolar disorder type I. They must have had at least one previous manic episode in the last two years and be hospitalized voluntarily for a current manic episode. Participants need to stop other psychotropic meds during screening.

Inclusion Criteria

Key

I am willing to stop taking all my psychiatric medications for the screening.

I have been diagnosed with bipolar disorder type I recently.

Treatment Details

The study tests if BHV-7000 is safe and effective for treating acute mania in bipolar disorder I patients compared to a placebo. It's designed to see how well it works when participants are experiencing an active manic episode.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: BHV-7000Experimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention